Fatih Inci1, Fatih Karatas. 1. Karabuk University Faculty of Medicine, Department of Medical Oncology, Karabuk, Turkey.
Abstract
PURPOSE: Paclitaxel has been associated with serum aminotransferase elevations, however, paclitaxel induced hepatosteatosis has not been evaluated systematically. This study assessed the rate of paclitaxel-related hepatosteatosis. METHODS: Forty one early breast cancer (BC) patients were included the study. Hepatic ultrasonograpy, demographic features and biochemical liver function tests before and after 12 weeks of paclitaxel were assessed. RESULTS: New-onset hepatosteatosis was developed in 26.7% of the patients. Baseline triglyceride>200mg/dL (OR, 11.25; p=0.015), LDH at baseline >191.48 IU/L (OR, 4.93; p=0.048), and total bilirubin >0.51 mg/dL after paclitaxel (OR, 6.17; p=0.042) were found as independent prognostic markers for new-onset hepatosteatosis. CONCLUSION: Paclitaxel may induce hepatosteatosis in patients with BC.
PURPOSE:Paclitaxel has been associated with serum aminotransferase elevations, however, paclitaxel induced hepatosteatosis has not been evaluated systematically. This study assessed the rate of paclitaxel-related hepatosteatosis. METHODS: Forty one early breast cancer (BC) patients were included the study. Hepatic ultrasonograpy, demographic features and biochemical liver function tests before and after 12 weeks of paclitaxel were assessed. RESULTS: New-onset hepatosteatosis was developed in 26.7% of the patients. Baseline triglyceride>200mg/dL (OR, 11.25; p=0.015), LDH at baseline >191.48 IU/L (OR, 4.93; p=0.048), and total bilirubin >0.51 mg/dL after paclitaxel (OR, 6.17; p=0.042) were found as independent prognostic markers for new-onset hepatosteatosis. CONCLUSION:Paclitaxel may induce hepatosteatosis in patients with BC.